News | October 25, 2021
Syngene reports better than expected revenues, margin pressure in Q1FY22: ICICI Direct
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, has announced it will invest in additional drug product manufacturing capabilities in Switzerland
The investment programme is expected to significantly reduce commercialisation lead times, costs and introduce more sustainable manufacturing processes
They enter into exclusive negotiations in a new drive to create a technology-driven leader for complex small molecules and ADCs of global scale
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The group, known as the HIV Obstruction by Programmed Epigenetics (HOPE) Collaboratory, will be led by researchers at Gladstone Institutes, Scripps Research Florida, and Weill Cornell Medicine. Their approach, which aims to both silence and permanently remove HIV from the body, takes advantage of knowledge about how other viruses have become naturally inactivated over time.
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
State-of-the-art R&D lab expands technical feasibility capabilities for long-acting delivery of small molecules, biologics, nucleotides
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
Subscribe To Our Newsletter & Stay Updated
